SG11201602614XA - Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines - Google Patents

Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines

Info

Publication number
SG11201602614XA
SG11201602614XA SG11201602614XA SG11201602614XA SG11201602614XA SG 11201602614X A SG11201602614X A SG 11201602614XA SG 11201602614X A SG11201602614X A SG 11201602614XA SG 11201602614X A SG11201602614X A SG 11201602614XA SG 11201602614X A SG11201602614X A SG 11201602614XA
Authority
SG
Singapore
Prior art keywords
difluorotetrahydrouridines
deoxy
synthetic route
route
synthetic
Prior art date
Application number
SG11201602614XA
Other languages
English (en)
Inventor
Hyeong-Wook Choi
Steven Mathieu
Frank Fang
Bryan Matthew Lewis
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of SG11201602614XA publication Critical patent/SG11201602614XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0201Oxygen-containing compounds
    • B01J31/0209Esters of carboxylic or carbonic acids
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0235Nitrogen containing compounds
    • B01J31/0237Amines
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0234Nitrogen-, phosphorus-, arsenic- or antimony-containing compounds
    • B01J31/0235Nitrogen containing compounds
    • B01J31/0244Nitrogen containing compounds with nitrogen contained as ring member in aromatic compounds or moieties, e.g. pyridine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00Separation of optically-active compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/06Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201602614XA 2013-10-29 2014-10-29 Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines SG11201602614XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361896703P 2013-10-29 2013-10-29
PCT/US2014/062874 WO2015066162A1 (en) 2013-10-29 2014-10-29 Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines

Publications (1)

Publication Number Publication Date
SG11201602614XA true SG11201602614XA (en) 2016-05-30

Family

ID=51982743

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201602614XA SG11201602614XA (en) 2013-10-29 2014-10-29 Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines

Country Status (19)

Country Link
US (3) US9834576B2 (enExample)
EP (1) EP3063164B1 (enExample)
JP (1) JP6427567B2 (enExample)
KR (1) KR102272773B1 (enExample)
CN (1) CN105683209B (enExample)
AU (1) AU2014342402B2 (enExample)
BR (1) BR112016008855B1 (enExample)
CA (1) CA2926734C (enExample)
ES (1) ES2712877T3 (enExample)
IL (1) IL244849B (enExample)
MX (1) MX363205B (enExample)
MY (1) MY176465A (enExample)
NZ (1) NZ718607A (enExample)
PH (1) PH12016500683B1 (enExample)
RU (1) RU2681939C2 (enExample)
SA (1) SA516371019B1 (enExample)
SG (1) SG11201602614XA (enExample)
WO (1) WO2015066162A1 (enExample)
ZA (1) ZA201602315B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2926734C (en) 2013-10-29 2022-03-15 Otsuka Pharmaceutical Co., Ltd. Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines
US11224610B2 (en) 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
EP4041743A4 (en) * 2019-10-08 2024-03-13 Otsuka Pharmaceutical Co., Ltd. HIGH PURITY 2'-DEOXY-2',2'-DIFLUORTETRAHYDROURIDINE AND METHOD FOR THE PRODUCTION THEREOF
PT4069254T (pt) 2020-02-25 2024-10-10 Otsuka Pharma Co Ltd Formas sólidas de dosagem oral compreendendo decitabina e cedazuridina
KR20230043904A (ko) 2020-07-24 2023-03-31 엘랑코 유에스 인코포레이티드 이속사졸린 화합물 및 이의 중간체의 제조 공정
CN113402573B (zh) * 2020-07-31 2023-06-20 集美大学 一种鞣质类化合物及其提取方法和应用
US20240279266A1 (en) * 2021-05-29 2024-08-22 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
TWI821074B (zh) * 2021-12-25 2023-11-01 台灣神隆股份有限公司 製備希達路里定(cedazuridine)的方法
US20230271996A1 (en) * 2021-12-25 2023-08-31 Scinopharm Taiwan, Ltd. Process for preparing cedazuridine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US4965374A (en) 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
FR2682112B1 (fr) 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5371210A (en) 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5521294A (en) 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
EP0876149A4 (en) 1995-12-22 2001-09-26 Univ East Carolina METHOD FOR TREATING DISORDERS CHARACTERIZED BY A CYTIDINE DEAMINASE OR DESOXYCYTIDINE DEAMINASE
US5760208A (en) 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
CN102241720B (zh) 2000-11-29 2014-01-29 三井化学株式会社 L-核酸衍生物及其合成方法
FI112640B (fi) 2000-12-22 2003-12-31 Kone Corp Hissin turvalaite
KR101108407B1 (ko) * 2006-06-21 2012-01-30 일라이 릴리 앤드 캄파니 젬시타빈 아미드 전구약물의 결정 형태, 그의 조성물 및 용도
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
CA2926734C (en) 2013-10-29 2022-03-15 Otsuka Pharmaceutical Co., Ltd. Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines

Also Published As

Publication number Publication date
PH12016500683A1 (en) 2016-05-30
US10526362B2 (en) 2020-01-07
EP3063164A1 (en) 2016-09-07
RU2681939C2 (ru) 2019-03-14
BR112016008855A2 (enExample) 2017-08-01
US11028119B2 (en) 2021-06-08
AU2014342402B2 (en) 2018-11-01
CA2926734C (en) 2022-03-15
AU2014342402A1 (en) 2016-04-21
KR20160083021A (ko) 2016-07-11
US20160237107A1 (en) 2016-08-18
EP3063164B1 (en) 2018-12-05
ZA201602315B (en) 2019-07-31
RU2016115523A3 (enExample) 2018-06-05
JP6427567B2 (ja) 2018-11-21
JP2017500281A (ja) 2017-01-05
ES2712877T3 (es) 2019-05-16
US20200123189A1 (en) 2020-04-23
IL244849B (en) 2019-10-31
KR102272773B1 (ko) 2021-07-02
CN105683209A (zh) 2016-06-15
US20180072768A1 (en) 2018-03-15
HK1223627A1 (en) 2017-08-04
SA516371019B1 (ar) 2018-01-23
MX2016005596A (es) 2016-12-09
CN105683209B (zh) 2019-03-08
WO2015066162A1 (en) 2015-05-07
US9834576B2 (en) 2017-12-05
NZ718607A (en) 2019-10-25
RU2016115523A (ru) 2017-12-04
BR112016008855B1 (pt) 2023-01-17
PH12016500683B1 (en) 2020-02-14
MY176465A (en) 2020-08-11
CA2926734A1 (en) 2015-05-07
IL244849A0 (en) 2016-05-31
MX363205B (es) 2019-03-13

Similar Documents

Publication Publication Date Title
IL240511A0 (en) Human antibodies to nav1.7
ZA201602315B (en) Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines
PT2970339T (pt) 1-hidroxibenzo-oxaboroles como agentes antiparasíticos
EP2990028A4 (en) THICKENING COMPOSITION
EP2970319A4 (en) 6-ACETYLMORPHINE ANALOGUE AND METHOD FOR THE SYNTHESIS AND USE
GB2516706B (en) Railway points
GB201312513D0 (en) 2 4 1 Technology
GB201321597D0 (en) Clip'n'Chill
GB201322203D0 (en) Deens' merger
AU5094P (en) Eggben 008 Salvia hybrid
AU5233P (en) Eggben 009 Salvia hybrid
GB201322287D0 (en) Inside - out trolley
GB201322568D0 (en) Taggstar 1
GB201309694D0 (en) Artist's implement
GB201310407D0 (en) Plantladders 3
GB201310285D0 (en) Twist-Away 270
GB201311522D0 (en) Concept 40
GB201311555D0 (en) Concept 60
GB201311528D0 (en) Concept 44
GB201311529D0 (en) Concept 3
GB201311530D0 (en) Concept 46
GB201311483D0 (en) Concept 48
GB201311486D0 (en) Concept 50
GB201311488D0 (en) Concept 51
GB201311489D0 (en) Concept 52